{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=42&state=Florida", "query": { "state": "Florida", "city": "Jacksonville", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 7628, "total_pages": 763, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=43&state=Florida&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=41&state=Florida&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T07:10:50.040Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00335153", "title": "Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Parkinson's Disease" ], "interventions": [ { "name": "Levodopa-carbidopa intestinal gel", "type": "DRUG" }, { "name": "CADD-Legacy® 1400 ambulatory infusion pump", "type": "DEVICE" }, { "name": "PEG tube", "type": "DEVICE" }, { "name": "J-tube", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 354, "start_date": "2008-01", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2015-01-16", "last_synced_at": "2026-11-05T07:10:50.040Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00335153" }, { "nct_id": "NCT03470545", "title": "Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obstructive Hypertrophic Cardiomyopathy" ], "interventions": [ { "name": "mavacamten", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MyoKardia, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 251, "start_date": "2018-05-29", "completion_date": "2020-05-06", "has_results": true, "last_update_posted_date": "2021-10-04", "last_synced_at": "2026-11-05T07:10:50.040Z", "location_count": 29, "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03470545" }, { "nct_id": "NCT00103506", "title": "Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib (VELCADE)", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride (DOXIL/CAELYX)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 646, "start_date": "2004-12", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2015-10-19", "last_synced_at": "2026-11-05T07:10:50.040Z", "location_count": 28, "location_summary": "Alabaster, Alabama • Surprise, Arizona • Berkeley, California + 25 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Surprise", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00103506" }, { "nct_id": "NCT03006068", "title": "A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis (UC)" ], "interventions": [ { "name": "Upadacitinib (ABT-494)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 950, "start_date": "2017-01-31", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-11-05T07:10:50.040Z", "location_count": 147, "location_summary": "Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 111 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03006068" }, { "nct_id": "NCT02790606", "title": "Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stenosis", "Restenosis" ], "interventions": [ { "name": "Covera(TM) Vascular Covered Stent", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "C. R. Bard", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 110, "start_date": "2016-07", "completion_date": "2019-03-16", "has_results": true, "last_update_posted_date": "2020-04-14", "last_synced_at": "2026-11-05T07:10:50.040Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02790606" }, { "nct_id": "NCT03975647", "title": "A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 466, "start_date": "2019-10-02", "completion_date": "2029-03-10", "has_results": true, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-11-05T07:10:50.040Z", "location_count": 321, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Goodyear, Arizona + 180 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03975647" }, { "nct_id": "NCT03977155", "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diarrhea-predominant Irritable Bowel Syndrome" ], "interventions": [ { "name": "BOS-589", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 133, "start_date": "2019-06-04", "completion_date": "2020-05-06", "has_results": true, "last_update_posted_date": "2021-06-07", "last_synced_at": "2026-11-05T07:10:50.040Z", "location_count": 58, "location_summary": "Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 48 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03977155" }, { "nct_id": "NCT00268489", "title": "Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2006-05", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-11-05T07:10:50.040Z", "location_count": 248, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Little Rock, Arkansas + 161 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Castro Valley", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00268489" }, { "nct_id": "NCT02465515", "title": "Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Albiglutide 30 mg", "type": "BIOLOGICAL" }, { "name": "Albiglutide 50 mg", "type": "BIOLOGICAL" }, { "name": "Albiglutide matching placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 9463, "start_date": "2015-07-01", "completion_date": "2018-03-14", "has_results": true, "last_update_posted_date": "2019-03-06", "last_synced_at": "2026-11-05T07:10:50.040Z", "location_count": 146, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 125 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465515" }, { "nct_id": "NCT00028925", "title": "Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "WBRT", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2001-11", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-11-05T07:10:50.040Z", "location_count": 23, "location_summary": "Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 19 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028925" } ] }